Dennis Demont

634 total citations
8 papers, 490 citations indexed

About

Dennis Demont is a scholar working on Molecular Biology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Dennis Demont has authored 8 papers receiving a total of 490 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Genetics and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Dennis Demont's work include Chronic Lymphocytic Leukemia Research (4 papers), Cancer therapeutics and mechanisms (1 paper) and Chemical Synthesis and Analysis (1 paper). Dennis Demont is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), Cancer therapeutics and mechanisms (1 paper) and Chemical Synthesis and Analysis (1 paper). Dennis Demont collaborates with scholars based in Netherlands and United States. Dennis Demont's co-authors include Allard Kaptein, Tjeerd Barf, Bas van de Kar, Michael Gulrajani, Todd Covey, Diana Mittag, Bart van Lith, Edwin de Zwart, Fanny Krantz and Roger G. Ulrich and has published in prestigious journals such as Blood, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Dennis Demont

8 papers receiving 474 citations

Peers

Countries citing papers authored by Dennis Demont

Since Specialization

Citations

This map shows the geographic impact of Dennis Demont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dennis Demont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dennis Demont more than expected).

Fields of papers citing papers by Dennis Demont

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dennis Demont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dennis Demont. The network helps show where Dennis Demont may publish in the future.

Co-authorship network of co-authors of Dennis Demont

This figure shows the co-authorship network connecting the top 25 collaborators of Dennis Demont. A scholar is included among the top collaborators of Dennis Demont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dennis Demont. Dennis Demont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors 2021 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Dennis Demont, Edwin de Zwart, (unknown), (unknown), Bas van de Kar, Allard Kaptein, Tjeerd Barf	2
2	Discovery of quinoline-based irreversible BTK inhibitors 2020 ·Bioorganic & Medicinal Chemistry Letters ·Gerjan de Bruin, Dennis Demont, Edwin de Zwart, (unknown), (unknown), Bas van de Kar, Bart van Lith, (unknown), Michael Gulrajani, Todd Covey, Allard Kaptein, Tjeerd Barf	7
3	Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Allard Kaptein, Gerjan de Bruin, (unknown), Bas van de Kar, Anouk de Jong, Michael Gulrajani, Dennis Demont, Todd Covey, Diana Mittag, Tjeerd Barf	1
4	Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies 2018 ·Blood ·Allard Kaptein, Gerjan de Bruin, (unknown), Bas van de Kar, Anouk de Jong, Michael Gulrajani, Dennis Demont, Todd Covey, Diana Mittag, Tjeerd Barf	71
5	Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile 2017 ·Journal of Pharmacology and Experimental Therapeutics ·Tjeerd Barf, Todd Covey, Raquel Izumi, Bas van de Kar, Michael Gulrajani, Bart van Lith, (unknown), Edwin de Zwart, Diana Mittag, Dennis Demont, (unknown), Fanny Krantz, Paul G. Pearson, Roger G. Ulrich, Allard Kaptein	272
6	Structure-based lead identification of ATP-competitive MK2 inhibitors 2011 ·Bioorganic & Medicinal Chemistry Letters ·Tjeerd Barf, Allard Kaptein, (unknown), (unknown), (unknown), Dennis Demont, Carsten Schultz‐Fademrecht, (unknown), (unknown), (unknown), Bert Kazemier, Bas van de Kar, (unknown), (unknown), (unknown), Ruben L. Smeets, Claudia L. Hofstra, Jorrit J. Hornberg, Arthur Oubrie	19
7	Identification of Substituted 6-Amino-4-phenyltetrahydroquinoline Derivatives: Potent Antagonists for the Follicle-Stimulating Hormone Receptor 2004 ·Journal of Medicinal Chemistry ·Nicole C.R. van Straten, (unknown), Dennis Demont, (unknown), Remco Merkx, Julia Oosterom, Jürgen Schulz, (unknown), C. Marco Timmers, (unknown)	67
8	A new cleavage strategy for the solid-phase synthesis of secondary amines 1997 ·Tetrahedron Letters ·Paolo Conti, Dennis Demont, (unknown), H. C. J. OTTENHEIJM, (unknown)	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact